Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by McAdam LLC

McAdam LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,644 shares of the biopharmaceutical company’s stock after selling 19 shares during the quarter. McAdam LLC’s holdings in Regeneron Pharmaceuticals were worth $2,779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC lifted its holdings in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $28,000. Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on REGN. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,102.19.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $941.39 on Thursday. The firm has a 50-day simple moving average of $1,098.29 and a two-hundred day simple moving average of $1,040.67. The stock has a market cap of $103.73 billion, a PE ratio of 27.81, a P/E/G ratio of 3.40 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter last year, the firm earned $8.79 EPS. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.